Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease

• US 20060263395A1
• Filed: 05/01/2006
• Published: 11/23/2006
• Est. Priority Date: 07/14/2000
• Status: Active Grant

• Current Assignee: Alchemia Oncology Limited
• Original Assignee: Meditech Research Limited (The Sustainable Nutrition Group Ltd.)
• Inventors: Fox, Richard, Brown, Tracey
• Granted Patent: US 8,388,993 B2
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis

Abstract

The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatmnet of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutice agent comprsing the step of administering to a submect in need thereof a therapeutically effective amount of hyaluronan.

Claims

1. A method of treating a drug resistant disease in a subject in need thereof comprising the step of administering to said subject a therapeutically effective amount of hyaluronan in conjunction with a chemotherapeutic agent such that said chemotherapeutic agent is more effective than when administered alone.

4. A method according to any one of claims 1 to 3, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate), CPT111, etoposide, plicamycin (Mithracin) and taxanes.

5. A method according to claim 1, wherein the drug resistant disease is a cellular proliferative disorder.

6. A method according to claim 5, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.

7. A method according to any one of claims 1 to 6, wherein the subject is mammal.

8. A method according to claim 7, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.

9. A method according to any one of claims 1 to 8, wherein the administration of hyaluronan, is prior to, together with, or subsequent to the administration of a chemotherapeutic agent.

10. A method according to any one of claims 1 to 9, wherein the administration of hyaluronan and/or chemotherapeutic agent is orally, topically, or parenterally.

11. A method according to claim 10, wherein the hyaluronan and/or chemotherapeutic agent is administered together with a pharmaceutically acceptable carrier, adjuvant, or vehicle.

12. A method according to claim 10 or claim 11, wherein parenteral administration is either by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.

2. A method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amount of hyaluronan.

3. A method of treating or preventing multidrug resistance or drug-resistant cells comprising the step of administering a sufficient amount of hyaluronan, prior to, together with, or subsequent to the administration of a chemotherapeutic agent.